Intradural extramedullary pleomorphic xanthoastrocytoma: A case report

Daniel R. Klinger¹, Rebecca L. Dillon², Nathan F. Clement¹, Francis J. Cloran³, Iren Horkayne-Szakaly⁴

Departments of ¹Neurosurgery, ²Radiology and Pathology, Brooke Army Medical Center, Roger Brooke Drive, Fort Sam Houston, San Antonio, Texas, United States, ³Department of Neuropathology and Ophthalmic Pathology, The Joint Pathology Center, Silver Spring, Maryland, United States.

E-mail: Daniel R. Klinger - daniel.r.klinger.mil@mail.mil; *Rebecca L. Dillon - rdillon8@gmail.com; Nathan F. Clement - nathan.f.clement.mil@mail.mil; Francis J. Cloran - francis.j.cloran.mil@mail.mil; Iren Horkayne-Szakaly - iren.horkayne-szakaly.civ@mail.mil

*Corresponding author: Rebecca L. Dillon, Department of Radiology, Brooke Army Medical Center, 3551 Roger Brooke Drive, Fort Sam Houston, San Antonio - 78219, Texas, United States.

INTRODUCTION

Pleomorphic xanthoastrocytomas (PXAs) are uncommon, low-grade glial neoplasms that involve the central nervous system; they account for 1% of all astrocytic tumors.⁶ They are typically seen supratentorially and arising in the temporal lobes.¹,²,⁷ These tumors are more commonly seen in children and young adults. They are typically seen supratentorially and arise in the temporal lobes.¹,²,⁷ Primary spinal PXAs are extremely rare, with only nine prior cases reported in the literature.³,⁴,⁶-⁹,¹²,¹³,¹⁷,¹⁸ Notably, the majority of these are intramedullary, with only one prior reported case of a primary spinal intradural, extramedullary PXA.¹³

CASE DESCRIPTION

A 43-year-old Caucasian male presented with 5 months of persistent posterior cervical neck pain radiating to the right shoulder, accompanied by paresthesias and right upper extremity radiculopathy. Although both his motor and sensory exams were intact, he was diffusely hyperreflexic (3+ bilateral biceps, brachioradialis, triceps, patella, and ankles [two beats of unsustained clonus in his right foot]) with bilateral Babinski signs. Hoffman’s signs were negative bilaterally.
The cervical MRI demonstrated a T1 isointense, T2 hyperintense, enhancing intradural, extramedullary mass measuring 2.4 × 1.4 × 1.1 cm at the C5–C6 level [Figure 1]. It was eccentrically located to the right, compressing the cervical spinal cord without abnormal hyperintense T2 spinal cord signal. The predominant differential diagnoses included a benign nerve sheath tumor versus meningioma.

He underwent a cervical laminectomy for gross total microsurgical resection of the tumor. The tumor was intradural and completely extramedullary; it appeared to arise from a C6 nerve rootlet. Gross total resection of the tumor was achieved and the entire lesion for sent for pathologic analysis.

**Histology**

The pathologic findings were most consistent with a PXA (WHO Grade II). The tumor was a well-circumscribed neuroepithelial neoplasm arranged in fascicles, sheets, and nests [Figure 2]. The tumor cells were variably pleomorphic and occasionally showed an epithelioid, xanthomatous, or ganglionic appearance. Scattered eosinophilic granular bodies and focal collections of perivascular lymphocytes were also noted. Up to 4–5 mitoses/10 high-power field were counted. Immunohistochemistry demonstrated GFAP, SOX10, synaptophysin, S100, SOX10 (red), and CD34 reactivity in most of the neoplastic cells. Staining with inhibin, NSE, MelanA, HMB45, NeuN, and H3K27M was negative. ATRX and INI1 were retained. No IDH1R132H mutation was detected. The reticulin stain highlighted only the blood vessels. A mutation of V600E in the BRAF gene was not detected on PCR. The DNA methylation analysis revealed no additional information. No reportable germline and somatic variants were detected with the PBTP Next-Generation Sequencing panel.

**Postoperative course**

The patient did well postoperatively, with improvement in his preoperative radicular pain and paresthesias. He was discharged home on postoperative day 2. In addition, he returned to work part-time 1 month following surgery, noting only mild right cervical paraspinal discomfort with activity.

The postoperative MRI demonstrated no residual disease, and the MRI of the brain, thoracic, and lumbar spine showed no other lesions. On follow-up MR 7 months later, the tumor had not recurred [Figure 3].

---

**Figure 1:** Sagittal (a) and axial T2-weighted (b) images demonstrated an intradural extramedullary cervical spine mass, displacing the spinal cord anteriorly and to the left. Axial T1 precontrast (c) and axial T1 postcontrast images (d) demonstrate heterogeneous enhancement of the mass, with a convex border abutting the spinal cord.

**Figure 2:** Hematoxylin and eosin stain (a) shows an astrocytic neoplasm with moderately pleomorphic nuclei and many eosinophilic granular bodies. Periodic acid–Schiff with diastase (b) highlights the eosinophilic granular bodies as well as blood vessels. By immunohistochemistry, the tumor cells show cytoplasmic positivity for GFAP (c) and synaptophysin (d), nuclear positivity for SOX10 (e), and both nuclear and cytoplasmic positivity for S-100 (f). (a,b) Viewed at ×200 magnification. (c-f) Viewed at ×400 magnification.
DISCUSSION

Frequency

PXAs are rare, slowly growing central nervous system neoplasms, thought to arise from subpial astrocytes or their precursors. These tumors were first described by Kepes et al. in 1979 and incorporated into the WHO classification of tumors in 1993. PXAs most commonly occur in children and young adults; however, they have been reported in patients ranging from 2 to 68 years in age. Up to 98% of PXAs occur supratentorially, with the most common site being the temporal lobes. Outcomes are generally favorable, with overall survival rates greater than 80% and 75% at 3 and 5 years, respectively.

Histopathology

Histologically, these neoplasms demonstrate large pleomorphic cells, either epithelioid or spindled, which are occasionally lipidized. Multinucleated cells and eosinophilic granular bodies are frequently seen. These neoplastic spindle cells may be arranged in fascicles, often accompanied by hypercellular reticulin staining. Focal collections of perivascular lymphocytes are also noted. Most are classified as the WHO Grade II; however, 15–20% demonstrate anaplastic features and are classified as the WHO Grade III. Anaplastic features include high mitotic activity (>5 mitoses/10 high-power fields) and areas of necrosis. BRAF mutations are found in approximately 75% of Grade II PXAs, with a lower frequency in anaplastic PXAs.

9 Prior cases reported of PXA in the spine

Only nine prior cases of primary spinal PXA have been reported; of these, only one was in an intradural, extramedullary location, the remainder being intramedullary lesions. Classically, PXAs present as cortically based tumors with cystic and solid components, usually isointense on T1-weighted and hyperintense on T2-weighted images, with marked postcontrast enhancement. Spinal PXAs [Table 1] are typically solid, enhancing masses, with only two demonstrating a cystic component. Most lesions occur in the cervical and thoracic spine, with only two reported cases involving the proximal lumbar spine at the T11-L2 and T12-L1 levels. Notably, the one prior reported case of an intradural, extramedullary PXA arose in the

| Reference | Age/ Sex | Location | MR characteristics | Extent of resection | Adjuvant therapy | Overall survival |
|-----------|----------|----------|--------------------|---------------------|------------------|-----------------
| Herpers et al., 1994 | 66/M | T2–T4 | Intramedullary | Partially cystic mass, enhancement of solid component | GTR followed by STR | RT following 2nd surgical resection | >8 months, alive at time of publication |
| Fouladi et al., 2001 | 12/M | Not reported | Solid mass, contrast-enhancing | STR | RT, CTX | Death 24 months after diagnosis |
| Nakamura et al., 2006 | 33/F | Cervical spine | Intramedullary | Partially cystic mass, enhancement of solid component | GTR | N/A | No recurrence at 36 months |
| Gill et al., 2010 | 23/F | T11–L2 | Intramedullary | Solid mass | STR followed by GTR | Oral CTX | No recurrence at 6 months |
| Simal-Julian et al., 2010 | 60/F | C4–C5 | Intramedullary | Solid mass, contrast-enhancing | GTR | N/A | No recurrence at 36 months |
| Das et al., 2014 | 15/M | C5–C6 | Intramedullary | Solid mass, contrast-enhancing | STR | N/A | Progressive disease at 24 months |
| Hong et al., 2017 | 31/M | T12–L1 | Intramedullary | Solid mass, contrast-enhancing. Leptomeningeal spread at diagnosis | STR | RT, CTX | Progressive disease, death 62 months after diagnosis |
| Sharma et al., 2017 | 23/F | T8–T10 | Intramedullary | Solid mass, contrast-enhancing | GTR | N/A | No recurrence at 12 months |
| Daoud et al., 2019 | 49/M | C3–C7 | Intradural, extramedullary | Solid mass, contrast-enhancing | STR | RT | No recurrence at 7 months |
| Index patient | 43/M | C5–C6 | Intradural, extramedullary | Solid mass, contrast-enhancing | GTR | N/A | No recurrence at ___ months |

GTR: Gross total resection; STR: Subtotal resection; RT: Radiation therapy; CTX: chemotherapy
Klinger, et al.: Intradural extramedullary spinal PXA

Surgical Neurology International • 2020 • 11(368) | 4

Intradural extramedullary spinal PXA

Surgical Neurology International • 2020 • 11(368) | 4

Surgical Neurology International • 2020 • 11(368) | 4

Surgical Neurology International • 2020 • 11(368) | 4

Surgical Neurology International • 2020 • 11(368) | 4

Figure 3: Sagittal T2-weighted (a) and T1 FS postcontrast (b) images of the cervical spine demonstrate no residual or recurrent tumor 7 months postoperatively.

cervical spine,[3] as in our patient. Imaging of the entire neuraxis is indicated to exclude additional lesions, although drop lesions from intracranial PXA have only rarely been reported.[2,14,20]

Treatment protocols

There are no well-established treatment protocols for spinal PXA. Of interest, 80% of patients (4 out of 5) who underwent gross total resection were alive and without evidence of recurrent disease at time of the publication of their respective articles [Table 1]. In contrast, 75% of patients (3 out of 4) who underwent subtotal resection had progressive disease, with half of them eventually succumbing to their tumors. While there is not strong evidence that radiotherapy or systemic chemotherapy increase survival for patients with primary PXA, they both have been used, especially in the setting of progressive and/or recurrent disease.[12] In our case, the lesion was fully excised, the patient’s symptoms resolved, and there was no evidence of tumor recurrence on the 7-month postoperative MR.

CONCLUSION

Here, we presented a patient with a primary WHO Grade II PXA involving the spinal cord in an intradural, extramedullary location. With gross total resection, the tumor has not recurred on 7-month postoperative follow-up.

Declaration of patient consent

Patient’s consent not required as patients identity is not disclosed or compromised.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Abid M, Haroon S, Memon AH, Ahmad Z, Hasan SH. Pleomorphic xanthoastrocytoma; clinicopathological spectrum of an intriguing neoplasm. Pak J Med Sci 2018;34:277-81.

2. Benjamin C, Faustin A, Snuderl M, Benjamin DP. Anaplastic pleomorphic xanthoastrocytoma with spinal leptomeningeal spread at the time of diagnosis in an adult. J Clin Neurosci 2015;22:1370-3.

3. Daoud EV, Wachsmann M, Richardson TE, Mella D, Pan E, Schwarzbach A. Spinal pleomorphic xanthoastrocytoma with a QKI-RAF1 fusion. J Neuropathol Exp Neurol 2019;78:10-4.

4. Das S, Yip S, Hukin J, Cochrane D, Dunham C. Pleomorphic xanthoastrocytoma of the spinal cord: Case report and literature review. Clin Neuropathol 2014;33:190-6.

5. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. PLoS One 2011;6:e17948.

6. Fouladi M, Jenkins J, Burger P, Langston J, Merchant T, Heideman R, et al. Pleomorphic xanthoastrocytoma: Favorable outcome after complete surgical resection. Neuro Oncol 2001;3:184-92.

7. Gill M, Pathak HC, Madan R, Bhattacharya S, Choudhary GS. Primary spinal pleomorphic xanthoastrocytoma. Neurol India 2010;58:771-3.

8. Herpers MJ, Freling G, Beuls EA. Pleomorphic xanthoastrocytoma in the spinal cord. Case report. J Neurosurg 1994;80:564-9.

9. Hong CS, Wang JL, Dornbos D 3rd, Joehlin-Price A, Elder JB. BRAF-mutated pleomorphic xanthoastrocytoma of the spinal cord with eventual anaplastic transformation. World Neurosurg 2017;98:871.e9-15.

10. Kepes JJ, Kepes M, Slowik F. Fibrous xanthomas and xanthosarcomas of the meninges and the brain. Acta Neuropathol 1973;23:187-99.

11. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumours of the Central Nervous system. Lyon: International Agency for Research on Cancer; 2016.

12. Mallick S, Giridhar P, Benson R, Melgandi W, Rath GK. Demography, pattern of care, and survival in patients with xanthoastrocytoma: A systematic review and individual patient data analysis of 325 cases. J Neurosci Rural Pract 2019;10:430-7.

13. Nakamura M, Chiba K, Matsumoto M, Ikeda E. Pleomorphic xanthoastrocytoma of the spinal cord. Case report. J Neurosurg Spine 2006;5:72-5.

14. Okazaki T, Kageji T, Matsuzaki K, Hirogiuchi H, Hirose T, Watanabe H, et al. Primary anaplastic pleomorphic xanthoastrocytoma with widespread neuroaxis dissemination at diagnosis-a pediatic case report and review of the literature. J Neurooncol 2009;94:431-7.

15. Pradhan P, Dey B, Srinivas BH, Jacob SE, Rathakrishnan RK. Clinicohistopathological and immunohistochemical profile of anaplastic pleomorphic xanthoastrocytoma: Report of five cases and review of literature. Int J Hematol Oncol Stem Cell Res 2018;12:265-72.

16. Shaikh N, Brahmbhatt N, Kruser TJ, Kam KL, Appin CL,
Wadhani N, et al. Pleomorphic xanthoastrocytoma: A brief review. CNS Oncol 2019;8:CNS39.

17. Sharma M, Velho V, Binayake R, Kharosekar H. Primary pleomorphic xanthoastrocytoma of the spinal cord: A case report and review of literature. Asian J Neurosurg 2017;12:566-9.

18. Simal-Julian, Sanchis-Martin R, Prat-Acin R, Miranda-Lloret P, Conde-Sardon R, Cardenas-Ruiz-Valdepenas E, et al. Spinal pleomorphic xanthoastrocytoma. Case report. Neurocirugia 2010;21:390-5.

19. Yan J, Cheng J, Liu F, Liu X. Pleomorphic xanthoastrocytomas of adults: MRI features, molecular markers, and clinical outcomes. Sci Rep 2018;8:14275.

20. Zhao X, Jiang X, Wang X. Spinal pleomorphic xanthoastrocytoma accompanied with periventricular tumor. Int J Clin Exp Pathol 2015;8:1036-40.

How to cite this article: Klinger DR, Dillon RL, Clement NF, Cloran FJ, Horkayne-Szakaly I. Intradural extramedullary pleomorphic xanthoastrocytoma: A case report. Surg Neurol Int 2020;11:368.